ATE411042T1 - Immunogene zusammensetzung umfassend tumorassoziiertes antigen und humanes zytokin - Google Patents

Immunogene zusammensetzung umfassend tumorassoziiertes antigen und humanes zytokin

Info

Publication number: ATE411042T1
Authority: AT; Austria
Prior art keywords: tumor; cytokine; cells; antigen; vaccines
Prior art date: 1996-07-25

Application number

AT97937043T

Other languages

English (en)

Inventor

John Hiserodt

Martin Graf

Gale Granger

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-25

Filing date

1997-07-25

Publication date

2008-10-15

1997-07-25 Application filed by Univ California filed Critical Univ California

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE411042T1 publication Critical patent/ATE411042T1/de

Links

108090000695 Cytokines Proteins 0.000 title abstract 8
102000004127 Cytokines Human genes 0.000 title abstract 8
206010028980 Neoplasm Diseases 0.000 title abstract 8
239000000427 antigen Substances 0.000 title abstract 5
102000036639 antigens Human genes 0.000 title abstract 5
108091007433 antigens Proteins 0.000 title abstract 5
230000002163 immunogen Effects 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 4
230000002349 favourable effect Effects 0.000 abstract 2
230000003248 secreting effect Effects 0.000 abstract 2
210000004881 tumor cell Anatomy 0.000 abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
108010002350 Interleukin-2 Proteins 0.000 abstract 1
102000000588 Interleukin-2 Human genes 0.000 abstract 1
108090000978 Interleukin-4 Proteins 0.000 abstract 1
102000004388 Interleukin-4 Human genes 0.000 abstract 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
230000000735 allogeneic effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000002619 cancer immunotherapy Methods 0.000 abstract 1
229940030156 cell vaccine Drugs 0.000 abstract 1
239000000284 extract Substances 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Oncology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AT97937043T 1996-07-25 1997-07-25 Immunogene zusammensetzung umfassend tumorassoziiertes antigen und humanes zytokin ATE411042T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2310896P	1996-07-25	1996-07-25
US2928696P	1996-10-29	1996-10-29
US08/901,225 US6277368B1 (en)	1996-07-25	1997-07-24	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Publications (1)

Publication Number	Publication Date
ATE411042T1 true ATE411042T1 (de)	2008-10-15

Family

ID=27362007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97937043T ATE411042T1 (de)	1996-07-25	1997-07-25	Immunogene zusammensetzung umfassend tumorassoziiertes antigen und humanes zytokin

Country Status (7)

Country	Link
US (5)	US6277368B1 (de)
EP (1)	EP0915708B1 (de)
AT (1)	ATE411042T1 (de)
AU (1)	AU3965597A (de)
CA (1)	CA2261837A1 (de)
DE (1)	DE69739046D1 (de)
WO (1)	WO1998004282A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7361332B2 (en)	1995-03-17	2008-04-22	The Regents Of The University Of California	Treating tumors using implants comprising combinations of allogeneic cells
US6406689B1 (en)	1995-10-03	2002-06-18	Frank W. Falkenberg	Compositions and methods for treatment of tumors and metastatic diseases
US6277368B1 (en)	1996-07-25	2001-08-21	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
ATE229810T1 (de)	1996-10-11	2003-01-15	Univ California	Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
JP2001522226A (ja)	1997-01-31	2001-11-13	リサーチコーポレイションテクノロジーズインコーポレイテッド	セミ−同種異系細胞での癌の免疫療法
WO1998039449A1 (en) *	1997-03-04	1998-09-11	Chiron Corporation	COMPOSITIONS AND USE OF M-CSF-alpha
AU7154598A (en) *	1997-04-23	1998-11-13	Regents Of The University Of California, The	A cell strain with activated anti-cancer cytotoxic activity
AU9589398A (en)	1997-10-10	1999-05-03	Applied Immunotherapeutics, Inc.	Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US6312700B1 (en) *	1998-02-24	2001-11-06	Andrew D. Weinberg	Method for enhancing an antigen specific immune response with OX-40L
EP1076564B1 (de) *	1998-04-02	2008-10-29	The Regents of the University of California	Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
US20070269455A1 (en) *	1998-05-26	2007-11-22	Genitrix, Llc	Cytokine-coated cells and methods of modulating an immune response to an antigen
WO2000026676A1 (en)	1998-11-03	2000-05-11	Cell Genesys, Inc.	Cancer-associated antigens and methods of their identification
US7217421B1 (en) *	1998-11-03	2007-05-15	Cell Genesys, Inc.	Cancer-associated antigens and methods of their identification and use
US7666609B1 (en)	1998-12-01	2010-02-23	Shanghai Cp Guojian Pharmaceutical Co. Ltd.	Method and composition for diagnosis of melanocytic lesions
AU3004700A (en) *	1999-02-24	2000-09-14	University Of Iowa Research Foundation, The	Methods and compositions for delivery of and specific immune response to nucleotide expression systems
US6501363B1 (en) *	1999-11-03	2002-12-31	Innosys, Inc.	Vertical transformer
US7361329B2 (en)	2000-04-21	2008-04-22	Chemocentryx, Inc.	Compositions for inducing an immune response
AUPQ755300A0 (en) *	2000-05-17	2000-06-08	Monash University	Immune potentiating compositions
WO2006031224A1 (en) *	2004-09-11	2006-03-23	Mosca Joseph D	Tumor-derived biological antigen presenting particles
US7371387B2 (en) *	2001-02-21	2008-05-13	Genitrix Llc	Vaccine compositions and methods of modulating immune responses
FR2822707A1 (fr) *	2001-04-03	2002-10-04	Neurotech	Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer
CU22999A1 (es) *	2001-12-04	2004-10-12	Centro Inmunologia Molecular	Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002085409A2 (en) *	2001-04-12	2002-10-31	Chemocentryx	Methods and compositions for inducing an immune response to an antigen
US20030044393A1 (en) *	2001-07-06	2003-03-06	Annie-Chen Tran	Method for increasing tumor cell immunogenicity using heat shock protein
US7446185B2 (en) *	2001-07-18	2008-11-04	The Regents Of The University Of California	Her2/neu target antigen and use of same to stimulate an immune response
AU2002341717A1 (en) *	2001-09-17	2003-04-01	Medcell Biologics, Llc.	Cell therapy system
CN1628167A (zh) *	2001-11-22	2005-06-15	医学基因公司	白细胞介素－2基因转移的淋巴因子活化的杀伤细胞
US20040076622A1 (en) *	2002-03-02	2004-04-22	Board Of Regents, The University Of Texas System	Local production and/or delivery of anti-cancer agents by stromal cell precursors
CA2479528A1 (en) *	2002-03-25	2003-10-02	Technologies Biolactis Inc.	Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
NZ536420A (en) *	2002-04-12	2008-04-30	Medarex Inc	Methods of treatment using CTLA-4 antibodies
US7629440B2 (en) *	2002-08-20	2009-12-08	Genitrix, Llc	Lectin compositions and methods for modulating an immune response to an antigen
US20040091503A1 (en) *	2002-08-20	2004-05-13	Genitrix, Llc	Lectin compositions and methods for modulating an immune response to an antigen
JP4754219B2 (ja)	2002-12-02	2011-08-24	アムジエン・フレモント・インコーポレイテツド	腫瘍壊死因子を対象とする抗体、およびそれらの使用
US20060062764A1 (en) *	2004-08-25	2006-03-23	Seshidar-Reddy Police	Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US8257715B1 (en) *	2004-08-26	2012-09-04	University Of Notre Dame	Tissue vaccines and uses thereof
US20060057127A1 (en) *	2004-09-10	2006-03-16	Pocheng Liu	Cytokine-expressing cellular vaccines for treatment of prostate cancer
CA2603191A1 (en)	2005-03-29	2006-10-05	The Board Of Trustees Of The University Of Illinois	Cancer vaccines and therapeutic methods
US9308252B2 (en)	2005-10-27	2016-04-12	Cook Biotech, Inc.	Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778360B2 (en) *	2005-10-27	2014-07-15	University Of Notre Dame	Extracellular matrix cancer vaccine adjuvant
US8778362B2 (en)	2005-10-27	2014-07-15	University Of Notre Dame	Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8802113B2 (en)	2005-10-27	2014-08-12	University Of Notre Dame	Extracellular matrix cancer vaccine adjuvant
US7901902B2 (en)	2006-07-27	2011-03-08	Biosante Pharmaceuticals, Inc.	Methods and compositions for identifying a cellular immune response against prostate cancer
KR20090058512A (ko)	2006-08-04	2009-06-09	아스트라제네카 아베	Ｅｒｂｂ2에 대한 인간 항체
US9320794B2 (en)	2006-11-13	2016-04-26	Immunovative Therapies, Ltd.	Ablative immunotherapy
US7972594B2 (en)	2006-11-13	2011-07-05	Immunovative Therapies Ltd.	Ablative immunotherapy
CA2676143A1 (en) *	2007-01-26	2008-07-31	University Of Louisville Research Foundation, Inc.	Modification of exosomal components for use as a vaccine
EP2132324B1 (de) *	2007-03-02	2012-04-25	Biosante Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
WO2009034574A2 (en) *	2007-09-12	2009-03-19	Yeda Research And Development Co. Ltd.	Methods of treating tumors in immune-privileged sites
EP2044949A1 (de) *	2007-10-05	2009-04-08	Immutep	Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
WO2009085237A2 (en) *	2007-12-21	2009-07-09	Cell Genesys, Inc.	Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
US9283266B2 (en) *	2008-02-28	2016-03-15	University Of Notre Dame	Metastasis inhibition preparations and methods
US8728465B2 (en) *	2008-06-17	2014-05-20	Cedars-Sinai Medical Center	Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
CN102076354A (zh) *	2008-07-03	2011-05-25	杜克大学	用于引发免疫应答的组合物和方法
US8840881B2 (en) *	2008-08-28	2014-09-23	Aduro Gvax Inc.	Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US8846059B2 (en)	2009-12-08	2014-09-30	University Of Notre Dame	Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) *	2009-12-18	2011-06-23	University Of Notre Dame	Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
US8735342B2 (en)	2010-01-27	2014-05-27	Neumedicines, Inc.	Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
CA2798074A1 (en)	2010-04-27	2011-11-03	The Johns Hopkins University	Immunogenic compositions and methods for treating neoplasia
US20120282215A1 (en) *	2011-01-13	2012-11-08	Oncbiomune, L.L.C.	Vaccination of Cancer Patients
WO2013043647A1 (en)	2011-09-19	2013-03-28	The Johns Hopkins University	Cancer immunotherapy
BR112014020502A2 (pt)	2012-02-22	2019-09-24	Univ Pennsylvania	sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
EP2858722B8 (de)	2012-06-08	2018-02-21	Aduro BioTech, Inc.	Zusammensetzungen und verfahren zur krebsimmuntherapie
SG11201502796RA (en)	2012-12-13	2015-05-28	Aduro Biotech Inc	Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014164396A1 (en) *	2013-03-12	2014-10-09	Michael Har-Noy	Ablative immunotherapy
JP2016524593A (ja)	2013-04-29	2016-08-18	メモリアルスローン−ケタリングキャンサーセンター	セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh)	2013-05-03	2019-11-12	加利福尼亚大学董事会	I型干扰素的环状二核苷酸诱导
CU24377B1 (es)	2013-05-18	2018-12-05	Aduro Biotech Inc	Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (de)	2013-05-18	2019-03-27	Aduro Biotech, Inc.	Zusammensetzungen und verfahren zur hemmung einer vom interferon-gen-stimulator unabhängigen signalisierung
US10176292B2 (en)	2013-07-31	2019-01-08	Memorial Sloan-Kettering Cancer Center	STING crystals and modulators
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
TWI706958B (zh)	2015-03-10	2020-10-11	美商艾杜諾生物科技公司	活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
US11103466B2 (en)	2016-05-10	2021-08-31	Jacinto Convit World Organization Inc.	Immunogenic composition for the treatment of cancer and methods of preparing the same
EP3507367A4 (de)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
NL2017267B1 (en)	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
US10913799B2 (en) *	2016-10-28	2021-02-09	Eli Lilly And Company	Anti-RANKL antibodies and uses thereof
CA3052463A1 (en)	2017-02-03	2018-08-09	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Oncolytic virus therapy
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
IL259392A (en)	2018-05-15	2018-08-01	Yeda Res & Dev	Vaccination with cancer neoantigens
KR102297470B1 (ko) *	2019-07-11	2021-09-02	가천대학교 산학협력단	줄기세포의 암세포로의 이동성 강화 방법
RU2722268C1 (ru) *	2019-12-06	2020-05-28	Федеральное государственное автономное образовательное учреждение высшего образования «Дальневосточный федеральный университет» (ДВФУ)	Способ биотерапии лабораторных крыс с перевитой глиобластомой

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE441425C (de)	1921-04-16	1927-03-03	Charles Joseph Belli	Federnde und elektrisch isolierende Kupplung
US4828991A (en)	1984-01-31	1989-05-09	Akzo N.V.	Tumor specific monoclonal antibodies
US4847201A (en)	1985-02-05	1989-07-11	Cetus Corporation	DNA encoding for CSF-1 and accompanying recombinant systems
US5109113A (en)	1986-05-02	1992-04-28	Genentech, Inc.	Membrane anchor fusion polypeptides
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5290551A (en)	1990-05-08	1994-03-01	Thomas Jefferson University	Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
WO1992004044A1 (en)	1990-09-06	1992-03-19	Schering Corporation	Use of il-4 to treat solid tumors
DE69114299T3 (de)	1990-09-14	2005-09-15	The Johns Hopkins University	Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
IE913264A1 (en)	1990-10-01	1992-04-08	Res Dev Foundation	Synergism of TNF and IL-4
US5681562A (en)	1991-06-25	1997-10-28	Sidney Kimmel Cancer Center	Lymphokine gene therapy of cancer
US5637483A (en)	1991-10-04	1997-06-10	Whitehead Institute For Biomedical Research	Irradiated tumor cell vaccine engineered to express GM-CSF
IL99821A (en)	1991-10-22	1996-07-23	Yeda Res & Dev	Antitumor vaccines comprising cells transfected with a gene encoding human il-6
EP0668781B1 (de)	1991-10-25	1999-12-29	Sidney Kimmel Cancer Center	Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
EP0569678A3 (de)	1992-03-13	1994-10-26	Yeda Res & Dev	Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
WO1995016775A1 (en)	1993-12-14	1995-06-22	Yajun Guo	Tumor cell fusions and methods for use of such tumor cell fusions
DE4406073A1 (de)	1994-02-24	1995-08-31	Univ Ludwigs Albert	Verfahren zur Herstellung von humanen, klonogenen Fibroblasten, Verfahren zur Gentransfizierung von Fibroblasten und so erhaltene Fibroblasten
DE4411425C2 (de)	1994-04-05	1996-07-04	Frank W Prof Dr Falkenberg	Verfahren zur Herstellung einer Tumorvakzine für die Aktive Spezifische Immuntherapie (ASI)
DE4412794A1 (de)	1994-04-14	1995-12-14	Univ Ludwigs Albert	Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5759535A (en)	1994-05-13	1998-06-02	Research Corporation Technologies, Inc.	Immunotherapeutic strategies for the treatment of cancer
DE4431401A1 (de)	1994-08-24	1996-02-29	Max Delbrueck Centrum	Lebendvakzine gegen Tumorerkrankungen
JP3822261B2 (ja)	1994-09-09	2006-09-13	財団法人癌研究会	癌の遺伝子治療剤
DE19606839C2 (de) *	1995-03-14	1998-09-24	Pritt Produktionsgesellschaft	Mehrschichtiges, flexibles Übertragungsband, ein Verfahren zu dessen Herstellung sowie dessen Verwendung in einem Handgerät
JP3201610B2 (ja)	1995-03-17	2001-08-27	ザリージェンツオブザユニバーシティオブカリフォルニア	腫瘍を処置する方法
DE19545351C1 (de)	1995-12-05	1997-07-31	Univ Ludwigs Albert	Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie
US6033674A (en) *	1995-12-28	2000-03-07	Johns Hopkins University School Of Medicine	Method of treating cancer with a tumor cell line having modified cytokine expression
US6051218A (en)	1996-02-02	2000-04-18	The Regents Of The University Of California	Tumor radiosensitization using gene therapy
US6277368B1 (en)	1996-07-25	2001-08-21	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
AU3889997A (en)	1996-08-16	1998-03-06	Johns Hopkins University School Of Medicine, The	Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
EP0930892A1 (de)	1996-10-16	1999-07-28	The Johns Hopkins University	Zytokin-erhoehte immuntherapie gegen gehirntumore
DE19716098A1 (de)	1997-04-17	1998-10-22	Univ Ludwigs Albert	Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden
US5891432A (en)	1997-07-29	1999-04-06	The Immune Response Corporation	Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same

1997
- 1997-07-24 US US08/901,225 patent/US6277368B1/en not_active Expired - Lifetime
- 1997-07-25 EP EP97937043A patent/EP0915708B1/de not_active Expired - Lifetime
- 1997-07-25 AT AT97937043T patent/ATE411042T1/de not_active IP Right Cessation
- 1997-07-25 AU AU39655/97A patent/AU3965597A/en not_active Abandoned
- 1997-07-25 CA CA002261837A patent/CA2261837A1/en not_active Abandoned
- 1997-07-25 DE DE69739046T patent/DE69739046D1/de not_active Expired - Fee Related
- 1997-07-25 WO PCT/US1997/013205 patent/WO1998004282A1/en not_active Ceased
2001
- 2001-06-05 US US09/875,349 patent/US7364726B2/en not_active Expired - Fee Related
- 2001-06-05 US US09/875,823 patent/US7264820B2/en not_active Expired - Fee Related
2007
- 2007-06-29 US US11/824,480 patent/US20080075744A1/en not_active Abandoned
- 2007-08-31 US US11/897,993 patent/US20080057029A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080075744A1 (en)	2008-03-27
US6277368B1 (en)	2001-08-21
DE69739046D1 (de)	2008-11-27
US7364726B2 (en)	2008-04-29
US20080057029A1 (en)	2008-03-06
US7264820B2 (en)	2007-09-04
AU3965597A (en)	1998-02-20
CA2261837A1 (en)	1998-02-05
WO1998004282A1 (en)	1998-02-05
EP0915708B1 (de)	2008-10-15
US20010038841A1 (en)	2001-11-08
EP0915708A1 (de)	1999-05-19
US20010036458A1 (en)	2001-11-01

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69739046D1 (de)	2008-11-27	Immunogene zusammensetzung umfassend tumorassoziiertes antigen und humanes zytokin
Yi et al.	2002	Optimizing dendritic cell‐based immunotherapy in multiple myeloma
Ullrich	1996	Does exposure to UV radiation induce a shift to a Th‐2‐like immune reaction?
Yi et al.	2010	Optimizing dendritic cell‐based immunotherapy in multiple myeloma: intranodal injections of idiotype‐pulsed CD40 ligand‐matured vaccines led to induction of type‐1 and cytotoxic T‐cell immune responses in patients
WO1998016238A3 (en)	1998-09-11	Cancer immunotherapy using tumor cells combined with mixed lymphocytes
DK1567155T3 (da)	2011-02-14	Administration of dendritiske celler, der er delvist modnet in vitro til behandlingen af tumorer
ATE188125T1 (de)	2000-01-15	Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
PL1622648T3 (pl)	2010-11-30	Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania
AU7980794A (en)	1995-05-08	Methods and compositions for microencapsulation of antigens for use as vaccines
MX2022008638A (es)	2022-08-08	Composiciones y metodos de inmunoterapia celular dirigida a bcma.
ATE389712T1 (de)	2008-04-15	Krebs immuntherapie mit semi-allogenen zellen
NZ512005A (en)	2004-01-30	New cancer treatments
WO2001054716A3 (en)	2002-03-07	Genetically engineered tumor cell vaccines
Shaim et al.	2015	Cord blood: a promising source of allogeneic natural killer cells for immunotherapy
Rizza et al.	2002	Cytokines as natural adjuvants for vaccines: where are we now?
WO2002053176A3 (en)	2002-12-19	An autologous anti-cancer vaccine
PL424035A1 (pl)	2019-01-02	Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową
WO2004022590A3 (en)	2005-01-20	Immunogenic muc1 glycopeptides
Timmerman	2003	Immunotherapy for lymphomas
CA2354045A1 (en)	2000-06-15	New cancer treatments
Marx et al.	2018	Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
DE69433110D1 (de)	2003-10-09	Allogenes vakzin und synthesemethode für selbiges
Galea et al.	2002	GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model
Dols et al.	2003	Allogeneic breast cancer cell vaccines
IZUMI et al.	1985	Enhanced induction of tumor-specific Lyt-1+ 2-T cell-mediated protective immunity by in vivo administration of interleukin 1